ABAT | 4-aminobutyrate aminotransferase | Disease related genes Enzymes FDA approved drug targets Mitochondrial proteins Plasma proteins
| | | | | Tissue enhanced |
ABL1 | C-abl oncogene 1, non-receptor tyrosine kinase | Cancer-related genes Disease related genes Enzymes FDA approved drug targets RAS pathway related proteins
| | | | | Expressed in all |
ACE | Angiotensin I converting enzyme | Candidate cardiovascular disease genes CD markers Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted membrane proteins Predicted secreted proteins
| | | | | Group enriched |
ACE2 | Angiotensin I converting enzyme 2 | Enzymes FDA approved drug targets Predicted membrane proteins
| | | | | Tissue enhanced |
ACHE | Acetylcholinesterase (Yt blood group) | Blood group antigen proteins Enzymes FDA approved drug targets Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enriched |
ADA | Adenosine deaminase | Disease related genes Enzymes FDA approved drug targets Plasma proteins
| | | | | Tissue enriched |
ADH1A | Alcohol dehydrogenase 1A (class I), alpha polypeptide | Enzymes FDA approved drug targets Plasma proteins
| | | | | Tissue enriched |
ADH1B | Alcohol dehydrogenase 1B (class I), beta polypeptide | Enzymes FDA approved drug targets Plasma proteins
| | | | | Group enriched |
ADK | Adenosine kinase | Disease related genes Enzymes FDA approved drug targets
| | | | | Expressed in all |
AKR1C2 | Aldo-keto reductase family 1, member C2 | Disease related genes Enzymes FDA approved drug targets
| | | | | Tissue enhanced |
AKR1D1 | Aldo-keto reductase family 1, member D1 | Disease related genes Enzymes FDA approved drug targets
| | | | | Tissue enriched |
ALAD | Aminolevulinate dehydratase | Disease related genes Enzymes FDA approved drug targets Plasma proteins
| | | | | Expressed in all |
ALDH2 | Aldehyde dehydrogenase 2 family (mitochondrial) | Cancer-related genes Enzymes FDA approved drug targets Mitochondrial proteins Plasma proteins Predicted secreted proteins
| | | | | Expressed in all |
ALK | Anaplastic lymphoma receptor tyrosine kinase | Cancer-related genes CD markers Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
ALOX5 | Arachidonate 5-lipoxygenase | Enzymes FDA approved drug targets
| | | | | Tissue enhanced |
ALPPL2 | Alkaline phosphatase, placental-like 2 | Enzymes FDA approved drug targets Plasma proteins Predicted secreted proteins
| | | | | Tissue enhanced |
AMY2A | Amylase, alpha 2A (pancreatic) | Enzymes FDA approved drug targets Predicted secreted proteins
| | | | | Tissue enriched |
AOC3 | Amine oxidase, copper containing 3 | Cancer-related genes Enzymes FDA approved drug targets Plasma proteins Predicted secreted proteins
| | | | | Tissue enhanced |
APEX1 | APEX nuclease (multifunctional DNA repair enzyme) 1 | Cancer-related genes Enzymes FDA approved drug targets Plasma proteins
| | | | | Expressed in all |
ATIC | 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase/IMP cyclohydrolase | Cancer-related genes Disease related genes Enzymes FDA approved drug targets Plasma proteins
| | | | | Expressed in all |
ATP1A1 | ATPase, Na+/K+ transporting, alpha 1 polypeptide | Cancer-related genes Enzymes FDA approved drug targets Plasma proteins Predicted membrane proteins Transporters
| | | | | Expressed in all |
ATP2C1 | ATPase, Ca++ transporting, type 2C, member 1 | Disease related genes Enzymes FDA approved drug targets Predicted membrane proteins Transporters
| | | | | Expressed in all |
ATP4A | ATPase, H+/K+ exchanging, alpha polypeptide | Enzymes FDA approved drug targets Plasma proteins Predicted membrane proteins Transporters
| | | | | Tissue enriched |
BCHE | Butyrylcholinesterase | Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted secreted proteins
| | | | | Tissue enhanced |
BCR | Breakpoint cluster region | Cancer-related genes Disease related genes Enzymes FDA approved drug targets
| | | | | Expressed in all |
BLVRB | Biliverdin reductase B (flavin reductase (NADPH)) | Enzymes FDA approved drug targets Plasma proteins Predicted secreted proteins
| | | | | Expressed in all |
BRAF | V-raf murine sarcoma viral oncogene homolog B | Cancer-related genes Disease related genes Enzymes FDA approved drug targets
| | | | | Expressed in all |
CA1 | Carbonic anhydrase I | Enzymes FDA approved drug targets Plasma proteins
| | | | | Group enriched |
CA14 | Carbonic anhydrase XIV | Enzymes FDA approved drug targets Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
CA2 | Carbonic anhydrase II | Disease related genes Enzymes FDA approved drug targets Plasma proteins
| | | | | Tissue enhanced |
CA3 | Carbonic anhydrase III, muscle specific | Enzymes FDA approved drug targets Plasma proteins
| | | | | Tissue enriched |
CA4 | Carbonic anhydrase IV | Disease related genes Enzymes FDA approved drug targets Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
CA7 | Carbonic anhydrase VII | Enzymes FDA approved drug targets
| | | | | Tissue enhanced |
CAT | Catalase | Cancer-related genes Disease related genes Enzymes FDA approved drug targets Plasma proteins
| | | | | Expressed in all |
CES1 | Carboxylesterase 1 | Enzymes FDA approved drug targets Plasma proteins Predicted secreted proteins
| | | | | Group enriched |
CFTR | Cystic fibrosis transmembrane conductance regulator (ATP-binding cassette sub-family C, member 7) | Cancer-related genes Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted membrane proteins Transporters
| | | | | Group enriched |
CHD1 | Chromodomain helicase DNA binding protein 1 | Enzymes FDA approved drug targets
| | | | | Expressed in all |
CKB | Creatine kinase, brain | Cancer-related genes Candidate cardiovascular disease genes Enzymes FDA approved drug targets Plasma proteins
| | | | | Expressed in all |
CKM | Creatine kinase, muscle | Candidate cardiovascular disease genes Enzymes FDA approved drug targets Plasma proteins
| | | | | Tissue enriched |
CKMT1A | Creatine kinase, mitochondrial 1A | Enzymes FDA approved drug targets Mitochondrial proteins Predicted secreted proteins
| | | | | Mixed |
CKMT1B | Creatine kinase, mitochondrial 1B | Enzymes FDA approved drug targets Mitochondrial proteins Predicted secreted proteins
| | | | | Mixed |
CKMT2 | Creatine kinase, mitochondrial 2 (sarcomeric) | Enzymes FDA approved drug targets Mitochondrial proteins Plasma proteins
| | | | | Group enriched |
COMT | Catechol-O-methyltransferase | Enzymes FDA approved drug targets Plasma proteins Predicted membrane proteins
| | | | | Expressed in all |
CPS1 | Carbamoyl-phosphate synthase 1, mitochondrial | Disease related genes Enzymes FDA approved drug targets Mitochondrial proteins Plasma proteins
| | | | | Group enriched |
CPT1A | Carnitine palmitoyltransferase 1A (liver) | Disease related genes Enzymes FDA approved drug targets Mitochondrial proteins Plasma proteins Predicted membrane proteins
| | | | | Expressed in all |
CPT2 | Carnitine palmitoyltransferase 2 | Disease related genes Enzymes FDA approved drug targets Mitochondrial proteins Plasma proteins
| | | | | Expressed in all |
CYP11B1 | Cytochrome P450, family 11, subfamily B, polypeptide 1 | Disease related genes Enzymes FDA approved drug targets Mitochondrial proteins
| | | | | Tissue enriched |
CYP17A1 | Cytochrome P450, family 17, subfamily A, polypeptide 1 | Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted secreted proteins
| | | | | Tissue enriched |
CYP19A1 | Cytochrome P450, family 19, subfamily A, polypeptide 1 | Cancer-related genes Disease related genes Enzymes FDA approved drug targets Predicted membrane proteins
| | | | | Tissue enriched |
CYP51A1 | Cytochrome P450, family 51, subfamily A, polypeptide 1 | Enzymes FDA approved drug targets Predicted membrane proteins
| | | | | Expressed in all |